Phosphodiesterase4 inhibitors are currently under development for the treatment of
respiratory diseases including asthma and chronic obstructive pulmonary disease. The …

Chronic respiratory diseases affect millions of people every day. According to the World
Health Organization estimates,~ 235 million people suffer from asthma,~ 64 million suffer …

Glucocorticosteroids remain the gold standard therapy for the prophylactic treatment of
asthma. Concerns regarding its long-term use particularly in young children has provided an …

Phosphodiesterases (PDE) belong to an important family of proteins that regulate the
intracellular levels of cyclic nucleotide second messengers. Targeting PDE with selective …

Background Many patients with chronic obstructive pulmonary disease (COPD) still
experience daily symptoms, exacerbations, and accelerated lung function decline, even …

Phosphodiesterase (PDE) 4, and to a lesser extent, PDE3/4 inhibitors have attracted
considerable interest as potential therapeutic agents for diseases including chronic …

Chronic obstructive pulmonary disease is characterized by a rapid decline in lung function
due to small airway fibrosis, mucus hypersecretion and emphysema. The major causative …

Phosphodiesterases (PDEs) are a superfamily of enzymes that catalyze the breakdown of
cAMP and/or cyclic guanosine monophosphate (GMP) to their inactive form. PDE4 is the …

Anti-inflammatory drugs are lacking in chronic obstructive pulmonary disease (COPD) and
inhibitors of the phosphodiesterase type-4 (PDE4) enzyme have been suggested to be an …

Introduction: At last, after many years of research, roflumilast has become the first oral
phosphodiesterase-4 inhibitor to be approved by the medical agencies as an add-on …